

CELL BIOTECH

Probiotics & Microbiome company



2026 2Q Earnings Release

2026. 08.

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual results to differ from those stated or implied in this material.

Q2 Earnings Summary

CELL BIOTECH

Revenue up 32.7% to KRW 15.8 billion, operating profit up 27.9% to KRW 1.6 billion

Domestic revenue up 25.9%, overseas revenue up 39.7%

Duolac brand sales up 3.7% to KRW 7.2 billion, OEM/ODM sales up 125% to KRW 7.1 billion,

Raw material sales down -18% to KRW 1.5 billion

(unit : KRW 100 mil)

	2025 2q	% of revenue	2026 2q	% of revenue	YoY(%)
Revenue	119.1		158.1		32.7
Domestic	59.9	50.3	75.4	47.7	25.9
Overseas	59.2	49.7	82.7	52.3	39.7
	2025 2q	Profit margin (%)	2026 2q	Profit margin (%)	YoY(%)
Operating profit	12.81	10.8	16.4	10.4	27.9
Net Profit	2.13	1.8	36.1	22.8	1593.0


Revenue trends

CELL BIOTECH

Q2 revenue KRW 15.8 billion, yoy + 32.7%, qoq + 8.3%


Quarterly revenue

(unit : KRW mil)



Full year revenue

(unit : KRW mil)



Profit trends


CELL BIOTECH

Q2 operating profit KRW 1.6 billion, yoy + 28%

Net Profit KRW + 3.6 billion, yoy + 1,593%


Quarterly profit

(unit : KRW mil)



Full year profit

(unit : KRW mil)




Revenue breakdown

CELL BIOTECH

Q2 revenue of Duolac brand + 3.7% to 7.2 KRW bil., OEM/ODM + 125.5% to 7.1 KRW bil., and raw material -17.9% to 1.5 KRW bil.

(unit : KRW mil)



Microbiome R&D

- 1) Microbiome First-in-Class anticancer pipeline 'PP-P8' clinical phase 1 IND submitted (Mar 5, 2021)
- 2) Acquisition European patent of PP-P8 (Apr 1, 2021) (patent number EP3453718)
- 3) Acquired US patent for Probiotics drug delivery system (22. 12. 20)
- 4) P8 anticancer mechanism paper MOA (23.06.07)
Anti-Cancer Roles of Probiotic-Derived P8 Protein in Colorectal Cancer Cell Line DLD-1, Int. J. Mol. Sci, 2023
- 5) Cellbiotech, Colorectal Cancer Drug Phase 1 Clinical Trial Plan Approved by Korea MFDS
(Mar 20, 2024)
- 6) Cellbiotech starts phase 1 of microbiome colorectal cancer drug 'PP-P8'

<https://www.hankyung.com/article/202502194939i>

No. 1 in global export for 13 consecutive years

- 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world for 13 consecutive years



<https://www.hankyung.com/article/202607228373i>

FDA GRAS World's Most Listed

1) Cellbiotech "11 types of lactic acid bacteria secured FDA GRAS certification... The World's Largest Holdings"



<https://www.hankyung.com/article/202402222016i>

2) Cellbiotech, Probiotics Leading... Global Leap



<https://www.dailypharm.com/Users/News/NewsView.html?ID=309331&REFERER=NP>

“Now is the Era of K-Probiotics”

– Cellbiotech’s ‘Duolac’ Achieves No. 1 Market Share in Denmark, the Home Country

1) Surpassing Local Brand ‘Lactocare’ --- Assuming the Top Spot with a 46.6% Market Share



<https://n.news.naver.com/mnews/article/016/0002614577?sid=101>

Consolidated Financial Summary

CELL BIOTECH

Income statement

(unit : KRW 100 mil., %)

	2025 2q		2026 2q	
	Amount	Ratio	Amount	Ratio
Revenue	119.1	100.0	158.1	100.0
Gross profit	88.9	74.7	115.7	73.2
SG&A expenses	76.1	63.9	99.3	62.8
Operating profit	12.8	10.8	16.4	10.4
Consolidated net income	2.1	1.8	36.1	22.8

Statement of financial position

(unit : KRW 100 mil., %)

	2025 .12	2026 2q
Assets	1,366	1,449
Current Assets	1037	1,098
Non current Assets	329	352
Liabilities	49	82
Current Liabilities	49	81
Non current Liabilities	1	1
Shareholder's Equity	1,316	1,367